Mannitol

證據等級: L5

預測適應症: 10 個

Mannitol: From Osmotic Diuretic Therapy to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Mannitol is a well-established osmotic diuretic, though the specific approved indication text is not captured in this evidence pack. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this prediction is currently supported by 0 clinical trials and only 1 loosely related publication.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (mannitol is a classic osmotic diuretic; specific approved-indication text is a data gap)
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)
TxGNN Prediction Score	99.97%
Evidence Level	L5 (model prediction only, no supporting studies)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for mannitol is currently unavailable (data gap). Based on general pharmacological knowledge, mannitol is an osmotic agent that draws free water from tissue into the vasculature and promotes osmotic diuresis — a mechanism historically applied to reduce intracranial/intraocular pressure and to manage oliguric states.

NSIAD is caused by a gain-of-function mutation in the vasopressin V2 receptor, leading to inappropriate free-water retention independent of ADH levels. In theory, an osmotic diuretic could promote free-water clearance and thereby correct the resulting hyponatremia. However, this mechanistic link is speculative: the standard-of-care for NSIAD is fluid restriction, urea, or vaptans — not mannitol. The only supporting literature is a general review on pitfalls in evaluating hyponatremia, which does not specifically discuss mannitol as a treatment for NSIAD.

Given the absence of any disease-specific study and the mismatch with established treatment paradigms, this prediction should be regarded as an unvalidated hypothesis generated by the knowledge graph rather than a clinically supported repurposing signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26706473	2016	Review	European Journal of Internal Medicine	General review of common pitfalls in evaluating hyponatremia; does not specifically address mannitol or NSIAD treatment.

Norway Market Information

Mannitol is currently not marketed in Norway; no authorization records are available in this dataset.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/product-label warnings and contraindications are flagged as a Blocking data gap in this evidence pack — this must be resolved before any S1 safety evaluation can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L5 — the prediction is supported by no clinical trials and only one tangentially related review article. The proposed mechanism also conflicts with established NSIAD management (fluid restriction, urea, vaptans), making the biological rationale weak rather than supportive.

To proceed, the following is needed:

Detailed mechanism of action (MOA) data for mannitol (currently a High-severity data gap)
TFDA/product-label warnings and contraindications (currently a Blocking data gap)
Disease-specific preclinical or clinical evidence directly evaluating mannitol in NSIAD or hyponatremia management
Clarification of whether the original approved indication(s) for mannitol are documented anywhere in the regulatory source data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.